Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
325.42
+5.17 (1.61%)
Oct 20, 2026, 4:00 PM EDT - Market closed
Krystal Biotech Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Krystal Biotech stock has a consensus rating of "Strong Buy" and an average price target of $395.44. The average 1-year stock price forecast is 21.52% higher than the current stock price, while the lowest is $284 (-12.73%) and the highest is $474 (+45.66%).
Price Target: $395.44 (+21.52%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Krystal Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 10 | 9 | 9 | 10 | 10 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 10 | 11 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citi | Citi | Buy Reiterates $386 → $416 | Buy | Reiterates | $386 → $416 | +27.83% | Oct 15, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $361 | Buy | Reiterates | $361 | +10.93% | Oct 15, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $400 | Buy | Maintains | $400 | +22.92% | Oct 9, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Initiates $441 | Buy | Initiates | $441 | +35.52% | Sep 24, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Reiterates $392 → $400 | Buy | Reiterates | $392 → $400 | +22.92% | Sep 21, 2026 |
Financial Forecast
Revenue This Year
498.17M
from 389.13M
Increased by 28.02%
Revenue Next Year
638.34M
from 498.17M
Increased by 28.14%
EPS This Year
7.66
from 6.84
Increased by 11.92%
EPS Next Year
9.00
from 7.66
Increased by 17.61%
EPS and Forward PE are based on non-GAAP adjusted numbers.